^
    5d
    Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2025
    Trial completion • Trial completion date
    |
    lenalidomide • Darzalex (daratumumab)
    7d
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Trial primary completion date: Oct 2041 --> Jan 2042
    Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    10d
    Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. (PubMed, Nephrol Dial Transplant)
    We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context...Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR...In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.
    Journal
    |
    IL6 (Interleukin 6) • CD40LG (CD40 ligand)
    |
    Blincyto (blinatumomab) • Darzalex (daratumumab) • Tecvayli (teclistamab-cqyv)
    10d
    Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=122, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Darzalex (daratumumab)
    11d
    Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=20, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Darzalex (daratumumab)
    11d
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2042 --> Oct 2041
    Enrollment open • Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    14d
    ATTAIN: Daratumumab and Belatacept for Desensitization (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab)
    19d
    Venetoclax-based therapy in high-risk patients with relapsed/refractory multiple myeloma harboring t(11;14): a case report and review of the literature. (PubMed, J Med Case Rep)
    Venetoclax combination regimen achieved excellent efficacy and safety in the treatment of relapsed/refractory multiple myeloma with t(11;14) in this case. The treatment of patients with relapsed and refractory multiple myeloma with t(11;14) by venetoclax still needs to be confirmed by more clinical studies.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Darzalex (daratumumab) • dexamethasone
    20d
    Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • sonrotoclax (BGB-11417)
    26d
    DREAMM-10: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (clinicaltrials.gov)
    P3, N=520, Recruiting, GlaxoSmithKline | Trial completion date: Apr 2032 --> Mar 2031 | Trial primary completion date: Dec 2030 --> Mar 2031
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    26d
    MagnetisMM-6: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (clinicaltrials.gov)
    P3, N=1116, Recruiting, Pfizer | Trial completion date: Nov 2031 --> Oct 2033 | Trial primary completion date: Mar 2028 --> Oct 2030
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Elrexfio (elranatamab-bcmm)
    29d
    Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    The patients were categorized based on their treatment regimens into the bortezomib-based group (V, 37 cases), bortezomib + lenalidomide-based group (VR, 28 cases), and daratumumab + bortezomib + lenalidomide-based group (DVR, 75 cases). In the new drug era, different induction chemotherapy regimens significantly impact hematopoietic stem cell mobilization and collection, with lenalidomide and daratumumab exhibiting notable effects. Timely administration of plerixafor for salvage mobilization based on CD34(+) cell counts on the day before collection improves both the success rate and quality rate of hematopoietic stem cell collection.
    Retrospective data • Journal
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • plerixafor